scholarly journals The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer

Oncotarget ◽  
2018 ◽  
Vol 9 (97) ◽  
pp. 37008-37016 ◽  
Author(s):  
Nobuhiro Hanai ◽  
Michi Sawabe ◽  
Takahiro Kimura ◽  
Hidenori Suzuki ◽  
Taijiro Ozawa ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
High Sensitivity ◽  
Prognostic Predictor ◽  
Modified Glasgow Prognostic Score

scholarly journals Assessment of Cachexia in Head and Neck Cancer Patients Based on a Modified Glasgow Prognostic Score

2016 ◽  
Vol 119 (2) ◽  
pp. 125-128
Author(s):  
Takashi Matsuzuka ◽  
Masahiro Suzuki ◽  
Satoshi Saijoh ◽  
Masakazu Ikeda ◽  
Mitsumasa Imaizumi ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Modified Glasgow Prognostic Score

scholarly journals Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kiyoshi Minohara ◽  
Takuma Matoba ◽  
Daisuke Kawakita ◽  
Gaku Takano ◽  
Keisuke Oguri ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Median Overall Survival ◽  
Prognostic Score ◽  
Performance Status ◽  
Glasgow Prognostic Score ◽  
Individual Treatment ◽  
Modified Glasgow Prognostic Score ◽  
The Impact

AbstractAlthough several prognostic factors in nivolumab therapy have been reported in recurrent or metastatic head and neck cancer (RM-HNC) patients, these factors remain controversial. Here, we conducted a multicenter retrospective cohort study to investigate the impact of clinico-hematological factors on survival in RM-HNC patients treated with nivolumab. We reviewed 126 RM-HNC patients from seven institutes. We evaluated the prognostic effects of clinico-hematological factors on survival. The median overall survival (OS) was 12.3 months, and the 1 year-OS rate was 51.2%. Patients without immune-related adverse events, lower relative eosinophil count, worse best overall response, higher performance status, and higher modified Glasgow Prognostic Score had worse survival. The score, generated by combining these factors, was associated with survival. Patients with score of 4–5 had worse survival than those with score of 2–3 and 0–1 [adjusted HR for PFS: score of 4–5, 7.77 (3.98–15.15); score of 2–3, 3.44 (1.95–6.06), compared to score of 0–1], [adjusted HR for OS: score of 4–5, 14.66 (4.28–50.22); score of 2–3, 7.63 (2.29–25.37), compared to score of 0–1]. Our novel prognostic score utilizing clinico-hematological factors might be useful to establish an individual treatment strategy in RM-HNC patients treated with nivolumab therapy.

scholarly journals Novel Prognostic Score for Recurrent or Metastatic Head and Neck Cancer Patients treated with Nivolumab: Japanese Multi-Institutional Cohort Study

2021 ◽  
Author(s):  
Kiyoshi Minohara ◽  
Takuma Matoba ◽  
Daisuke Kawakita ◽  
Gaku Takano ◽  
Keisuke Oguri ◽  
...  
Keyword(s):  
Cohort Study ◽  
Head And Neck Cancer ◽  
Prognostic Factors ◽  
Head And Neck ◽  
Neck Cancer ◽  
Prognostic Score ◽  
Performance Status ◽  
Glasgow Prognostic Score ◽  
Individual Treatment ◽  
The Impact

Abstract Although several prognostic factors in nivolumab therapy have been reported in patients with recurrent or metastatic head and neck cancer (RM-HNC), these factors remain controversial. Here, we conducted a multicenter retrospective cohort study to investigate the impact of clinico-hematological factors on survival in RM-HNC patients treated with nivolumab. We retrospectively reviewed 126 RM-HNC patients from seven institutes. We evaluated the prognostic effects of clinico-hematological factors on survival using Cox proportional hazard models. The median overall survival (OS) was 12.3 months, and the 1 year-OS rate was 51.2 %. Patients without immune-related adverse events, lower relative eosinophil count, worse best overall response, higher performance status, and higher modified Glasgow Prognostic Score had significantly worse survival rates. The prognostic score, generated by combining these significantly worse prognostic factors, was more closely associated with prognosis than each factor (p for trend<0.001). Our novel prognostic score utilizing clinico-hematological factors might be useful to establish an individual treatment strategy in patients with RM-HNC treated with nivolumab therapy.

Sign in / Sign up

Export Citation Format

Share Document